Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients

04-Dec-2008 - Switzerland

Addex Pharmaceuticals started a Phase IIb trial of ADX10059 as an add-on therapy to proton pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms. The standard dose of PPI does not control GERD adequately in about 40% of patients. ADX10059 is a first-in-class reflux inhibitor that works by selectively inhibiting the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation. This approach may lead to a new class of drugs that addresses the causes of GERD rather than the symptoms.

Chief Medical Officer Charlotte Keywood said: "The aim of this trial is to give us information on the clinical effects of reflux inhibition by an mGluR5 inhibitor in patients who continue to have breakthrough symptoms whilst on PPIs. This study also may provide information on the most appropriate dose of ADX10059."

Study 205 is a double-blind, placebo-controlled, multi-center U.S. and European Phase IIb trial in about 280 GERD patients who are partial responders to proton pump inhibitors (PPIs). Patients in the trial will continue taking PPIs, the gold standard treatment for GERD, which work by reducing the acidity of the stomach contents. There will be a baseline symptom evaluation period followed by four weeks of administration of twice-daily ADX10059 (50mg, 100mg or 150mg). The primary endpoint is patient reported symptom control compared to baseline. Data are expected to be reported in late 2009.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

How to use antibodies to control chemical reactions - Researchers developed a strategy to synthesize functional molecules with specific diagnostic antibodies

How to use antibodies to control chemical reactions - Researchers developed a strategy to synthesize functional molecules with specific diagnostic antibodies

Novel gene variants identified in male breast cancer

Ariadne Genomics and Jubilant Biosys Announce Strategic Alliance - Providing Curated Metabolic, Signaling, and Disease Pathway Databases as an Add-on to Pathway Analysis Software

Multiplicom receives €200,000 grant for novel non-invasive pre-natal test - IWT grant to support development of early aneuploidy detection during pregnancy

AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform

TranScrip Partners appoints David Oxlade as Chairman of the Board

Sequenom Announces Exclusive Licensing Agreement with Genomic Nanosystems for Digital PCR Technologies and Methods Patents

Intercell announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections - Second part of the study in the target population of elderly subjects will be initiated

Excellent early results in large OvPlex ovarian cancer biomarker study

Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial

Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board